Measles, Mumps, and Rubella (MMR) Immunity in College Students

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00962819
Recruitment Status : Completed
First Posted : August 20, 2009
Last Update Posted : March 5, 2014
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Sri Edupuganti, MD MPH, Emory University

Brief Summary:
This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar outbreaks of measles and rubella. A total of 70 to 80 college students (age 18 to 22) on the Emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. Their medical records will be verified for documentation of immunization with MMR vaccine prior to enrollment in the study. If a study volunteer is found to not have MMR immunity, they will be offered an MMR-II vaccine. For this group, additional blood specimens will be obtained.

Condition or disease Intervention/treatment
Measles Mumps Rubella Biological: MMR vaccine

Detailed Description:
No additional description needed.

Study Type : Observational
Actual Enrollment : 74 participants
Time Perspective: Cross-Sectional
Official Title: Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine
Study Start Date : March 2010
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Measles Mumps Rubella
U.S. FDA Resources

Group/Cohort Intervention/treatment
College-aged students who were immunized with MMR.
Biological: MMR vaccine
People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
Other Name: No other names

Primary Outcome Measures :
  1. Levels of mumps antibody and levels of memory B and T cell responses [ Time Frame: Day 1 for all participants except for those who receive MMR vaccine, there will be additional outcome measures on Day 0, 7, 14 and 28 post-vaccination. ]
    Cross sectional measurement of antibodies to mumps. measles or rubella

Secondary Outcome Measures :
  1. Determine proportion of college-aged students who are seronegative for mumps [ Time Frame: outcome measurement on Day 1 ]
    Cross-sectional measurement of antibodies to mumps, measles and rubella

Biospecimen Retention:   Samples With DNA
Whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 24 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects for this study will be 18-22 year olds recruited from Emory University's student population who have received two age-appropriate doses of the MMR-II vaccine.

Inclusion Criteria:

  • Ability and willing to provide an informed consent
  • Documented receipt of MMR-II vaccination in childhood
  • Not pregnant

Exclusion Criteria

  • No history of HIV infection.
  • Immunocompromised health status due to HIV infection, cancer, diabetes, liver, lung or kidney diseases, autoimmune diseases, history of splenectomy.
  • Use of immunosuppressive medications within last 2 to 3 months (oral or parenteral corticosteroids or cytotoxic medications)
  • Medical conditions that require the use of immunosuppressive medications
  • Received blood or blood products within the last 30 days
  • Any vaccines received in the last 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00962819

United States, Georgia
The Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, United States, 30030
Sponsors and Collaborators
Sri Edupuganti, MD MPH
Merck Sharp & Dohme Corp.
Principal Investigator: Srilatha Edupuganti, MD Emory University

Additional Information:
Responsible Party: Sri Edupuganti, MD MPH, Assistant Prfessor, Emory University Identifier: NCT00962819     History of Changes
Other Study ID Numbers: IRB00007373
First Posted: August 20, 2009    Key Record Dates
Last Update Posted: March 5, 2014
Last Verified: March 2014

Keywords provided by Sri Edupuganti, MD MPH, Emory University:
Mumps antibodies
Mumps immunity

Additional relevant MeSH terms:
Morbillivirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Rubivirus Infections
Togaviridae Infections
Rubulavirus Infections
Parotid Diseases
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Immunologic Factors
Physiological Effects of Drugs